For laboratory / research use only — not for human consumption. Read full disclaimer.

Metabolism tool

Body Composition & Metabolic Estimator

Mifflin-St Jeor BMR and TDEE with overlaid projected fat-loss curves for low, mid and high research-stage doses of GLP-1 class peptides.

Subject parameters

yrs
cm
kg

Approximations from published GLP-1 / dual-agonist trial literature.

weeks

BMR

1843 kcal/d

TDEE

2856 kcal/d

Est. weekly Δ

-0.47 kg/wk

Projected cumulative reduction

-5.6 kgwk 12

Projections assume a 7,700 kcal-per-kilogram body-fat equivalency and a stable energy intake. Real-world research subjects typically plateau at 65 – 80% of the projected curve due to metabolic adaptation.

The Mifflin-St Jeor equation

BMR is calculated using the Mifflin-St Jeor equation, the most accurate predictor of resting energy expenditure in published validation studies. TDEE is BMR multiplied by an activity factor between 1.2 (sedentary) and 1.9 (very active). Projected fat-loss curves assume a 7,700 kcal-per-kilogram body-fat equivalency and a sustained energy deficit proportional to the published-trial deficit for the selected research dose intensity.

Caveats

  • Real-world research subjects plateau at 65 – 80% of the projected curve due to metabolic adaptation.
  • Body recomposition (concurrent lean-mass changes) is not modelled.
  • Trial data are derived from published GLP-1 and dual-agonist literature; individual responses vary widely.

Supporting research

  • Mifflin MD et al., A new predictive equation for resting energy expenditure, Am J Clin Nutr, 1990.
  • Wilding JPH et al., Once-Weekly Semaglutide in Adults with Overweight or Obesity, NEJM, 2021.
  • Jastreboff AM et al., Tirzepatide Once Weekly for the Treatment of Obesity, NEJM, 2022.

Related tools